There are over 330 million people living on the planet affected by one of over 6,000 identified genetic rare diseases (RD). They urgently need timely diagnosis and development of specific treatments. Although Europe leads the way in RD research, there is a clear gap in research and innovation (R...

Microorganisms that live on and within our bodies impact almost all of our biological processes. Many areas of research are changing with the realisation that microbiota, their genes and the way they interact with host genetics, are integral to in both basic and applied biology, with direct...

DYNAMITE is the acronym for the project 'Systems-level tracking of dynamics in T cell expansion for precision oncology'. DYNAMITE aims to enhance the success of immune checkpoint inhibition (ICI) therapy in colorectal cancer (CRC) by developing a novel class of predictive biomarkers. While ICI has...

Small Cell Lung Cancer (SCLC) is considered a ‘recalcitrant’ disease, characterized by poor survival outcomes and lack of effective treatment options. Recently, the addition of immune checkpoint inhibitors (ICI) to chemotherapy has become standard of care for advanced SCLC, providing a modest...

The European Rare Diseases Research Alliance (ERDERA) aims to improve the health and well-being of the 30 million people living with a rare disease in Europe, by making Europe a world leader in Rare Disease (RD) research and innovation, to support concrete health benefits to rare disease patients,...

Xatardia scabra is an endemic species found in the eastern Pyrenees, inhabiting the scree slopes of alpine and subalpine regions between (1600) 1900-2900 meters above sea level. It is considered vulnerable on the French Red List and is one of the plants being studied in various European projects...